OncoTherapy Science, Inc. (TYO:4564)
15.00
0.00 (0.00%)
Nov 18, 2026, 10:19 AM JST
OncoTherapy Science Revenue
OncoTherapy Science had revenue of 165.00M JPY in the quarter ending September 30, 2026, a decrease of -28.26%. This brings the company's total for the last twelve months to 712.00M, down -25.52% year-over-year. In the fiscal year ending March 31, 2026, OncoTherapy Science had annual revenue of 808.00M with 7.73% growth. That makes OncoTherapy Science the 40,374th largest company in the world by revenue and 3,819th in Japan.
Revenue (ttm)
712.00M
Revenue Growth
-25.52%
P/S Ratio
8.60
Revenue / Employee
15.48M
Employees
46
Market Cap
6.12B
Revenue by Segment
- Cancer Precision Medicine Related Business 806.20M 99.7%
- Pharmaceutical Research and Development and Related Businesses 2.64M 0.3%
Fiscal year ended Mar 31, 2026 See the full OncoTherapy Science breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 808.00M | 58.00M | 7.73% |
| Mar 31, 2025 | 750.00M | 140.00M | 22.95% |
| Mar 31, 2024 | 610.00M | -524.00M | -46.21% |
| Mar 31, 2023 | 1.13B | -19.00M | -1.65% |
| Mar 31, 2022 | 1.15B | 821.00M | 247.29% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Kidswell Bio | 5.79B |
| Soiken Holdings | 3.87B |
| CellSource | 3.67B |
| StemCell Institute | 2.81B |
| Carna Biosciences | 756.57M |
| Chiome Bioscience | 615.15M |
| Nano Holdings | 202.00M |
| CellSeed | 161.00M |